Rare Thrombotic Diseases Consortium

Image of a Girl and her Mother talking together

Duke University Medical Center

Mayo Clinic

University of North Carolina

University of Wisconsin

The Centers for Disease Control

Durham VA Medical Center

Contact Information

	University of North Carolina Thrombophilia Program

Contact Information:

Robert Roubey, M.D.
Co-Investigator
Division of Rheumatology & Immunology
Department of Medicine
University of North Carolina
Chapel Hill, NC 27599

Stephan Moll, M.D.
Co-Investigator
Department of Medicine
Division of Hematology-Oncology
UNC School of Medicine
Chapel Hill , NC 27599
CB 7035

Caron Misita, PharmD
Research Physician Extender
Department of Medicine
Division of Hematology-Oncology
UNC School of Medicine
Chapel Hill , NC 27599
CB 7035

About Us:

The UNC Thrombophilia Program's mission is (1) to provide the best medical care (prevention, diagnosis and treatment) to patients with thrombophilia, thrombotic disorders (venous and arterial) and premature arteriosclerosis, (2) to conduct clinical research on epidemiology, diagnosis, treatment and prevention of these disorders, and to collaborate with basic researchers to answer basic research questions on thrombosis, and (3) to educate public, patients and health care providers on thrombophilia. The UNC Thrombophilia Program is part of UNC's " Carolina Cardiovascular Biology Center " (http://ccbc.unc.edu ).

Dr. Moll is co-investigator of the "Rare Thrombotic Diseases Consortium (RTDC)", co-investigator of the Antiphospholipid Syndrome Collaborative Registry (APSCORE), and participates in a number of clinical studies relating to thrombosis and thrombophilia. He is the Chairman of the Medical and Scientific Advisory Board (MASAB) of the national patient advocacy group NATT (National Alliance for Thrombosis and Thrombophilia; www.nattinfo.org) and is a volunteer contributor to the thrombophilia patient education website www.fvleiden.org.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) (www.apscore.org) is a multi-institutional, multi-specialty collaborative registry to establish a national registry for patients with antiphospholipid antibodies and antiphospholipid antibody syndrome (APS). The Registry is collecting and updating clinical, demographic, and laboratory data on patients with APS, asymptomatic patients with antiphospholipid antibodies, and certain individuals with serological and/or clinical features that fall within an expanded concept of APS. The Registry will also serve as a repository for sera, plasma, and genomic DNA. The current enrollment for the Registry is more than 800 patients, and these patients are potentially available for clinical research protocols proposed and agreed upon by the P.I., Dr. Robert Roubey, and co-investigators of the Registry.

Useful Links:

Carolina Cardiovascular Biology Center

Antiphospholipid Syndrome Collaborative Registry (APSCORE)

National Alliance for Thrombosis and Thrombophilia

Thrombophilia Patient Education Website

RTDC Clinical Trials:

5806: Genetics of antiphospholipid antibody syndrome (APS)

Other Clinical Trials:

"Rare Compound Thrombophilia Study"
International retrospective registry of 100 individuals with rare compound thrombophilia (homozygous factor V Leiden plus heterozygous II20210 mutation; heterozygous factor V Leiden plus homozygous II20210 mutation; homozygous factor V Leiden plus homozygous II20210 mutation) to assess thrombophilic risk associated with these mutations. Study completed. Abstract published. Full manuscript pending.

"INR Determination By Plasma-Based Methods Versus Point-Of-Care Instruments In Patients With Antiphospholipid Antibody Syndrome on Anticoagulants"
One-center (UNC) prospective study. Ongoing.

Publications:

Moll S , Ortel T: Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants. Ann Intern Med,1997;127:177-185.

Moll S , Kudrik FJ, Thomas DB: Images in Hematology: Catastrophic Antiphospholipid Antibody Syndrome. Am J Hematol 2003:278-9.

Moll S, Musty M, et al: Thrombophilic Risk of Individuals with Rare Factor V Leiden and Prothrombin 20210 Compound Thrombophilias. Blood 2003;102:abstract 2013.